Skip to content
About
Leadership
Executive Team
Board of Directors
Facilities
Therapeutic Areas Overview
Central Nervous System
Fibromyalgia
Posttraumatic Stress Disorder
Long COVID
Cocaine Intoxication
Migraine
Depression
Immunology
Organ Transplant Rejection
Gastro-Intestinal Cancers
Infectious Disease
Monkeypox
Smallpox
COVID-19
Rare Disease
Prader-Willi Syndrome
Pipeline
Central Nervous System
TNX-102 SL
TNX-601 ER
TNX-1300
TNX-1900
Immunology
TNX-1500
TNX-1700
Infectious Disease
TNX-801
TNX-1850
Rare Disease
TNX-2900
Scientific Presentations
Expanded Access Policy
Clinical Trials
News & Events
Tonix in the News
Press Releases
Investor Presentations
IR Events
Op-eds
Investors
News & Events
Presentations
Multimedia
Financial Info
Stock Data
SEC Filings
Governance
Careers
Contact Us
Tonix is enrolling in a Phase 3 study for Fibromyalgia, and Phase 2 studies for Chronic Migraine and Major Depressive Disorder. Please visit
Clinical Trials
.
November 2021
TNX-601 CR*: a Once-Daily Formulation of Tianeptine in Development for the Treatment of Major Depressive Disorder
